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ABSTRACT
Objectives: The role of perioperative hemofi ltration (HF) in adult patients with impaired renal function 
undergoing cardiac surgery is controversial. There are suggestions that it may be benefi cial for high risk patients 
undergoing prolonged cardiopulmonary bypass (CPB) surgery. However, long term outcomes in coronary artery 
bypass graft (CABG) surgery patients have not been investigated. 
Methods: To address this we retrospectively followed 7620 patients who underwent CABG between April 
2001 and March 2006. Logistic regression was used to risk adjust in-hospital outcomes. Cox proportional 
hazards analysis was used to risk adjust Kaplan-Meier freedom from death curves. Outcomes were adjusted for 
American Heart Association and American College of College of Cardiology recommended variables. 
Results: 113 patients had intraoperative HF, 38 had postoperative HF and control group of 7006 that 
had no HF. After adjusting for differences in case-mix, patients with preoperative kidney disease who 
received postoperative HF proportionately had signifi cantly higher rates of hospital deaths as compared with 
intraoperative HF patients. In addition, 5-year follow-up risk-adjusted freedom from death indicated signifi cant 
differences between intraoperative HF group and postoperative HF patients. 
Conclusions: These fi ndings support the hypothesis that after adjusting for differences in case mixes, the 
use of intraoperative hemofi ltration may offer superior short term clinical outcomes and longer-term survival 
benefi ts for patients with preoperative kidney disease.
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INTRODUCTION 
Cardiopulmonary bypass is known to adversely impact upon perioperative renal 
function in particular for individuals with diabetes mellitus or an existing renal 
impairment [1]. Renal injury may occur resulting in acute kidney injury (AKI) which is 
the standard term for an abrupt and sustained decrease in renal function resulting in the 
retention of nitrogenous (urea and creatinine) and non-nitrogenous waste products. 
Depending on the severity and duration of the renal dysfunction, this accumulation is 
accompanied by metabolic disturbances, such as metabolic acidosis and hyperkalaemia, 
changes in body ϐluid balance, and effects on many other organ systems. Deϐinitions of 
AKI have varied from the severe (i.e., that require dialysis) to the slight increases in 
serum creatinine concentration by 44·2 μmol/L [2]. Severe AKI, deϐined as renal failure 
that requires renal replacement therapy is a major complication of cardiac surgery 
with an associated mortality of 60-100% when treated with standard hemodialysis [3]. 
More recently, continuous renal replacement techniques have been introduced, which 
circumvent the hemodialysis instability associated with intermittent hemodialysis and 
its limited ability to control the patient’s volume state [4]. One such form of continuous 
renal replacement therapy is continuous venovenous hemodialysis (CVVH) that has 
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been shown to substantially facilitate improved care of patients with severe AKI after 
cardiac operations when used early and intensively [5].
Hemoϐiltration was introduced in the 1980s for CPB management [6-9], and has 
been shown in pediatric cardiac surgery to be effective at regulating hemostasis, 
removal of cytokines and complement components [10]. Similarly, in adults zero-
balance hemoϐiltration was shown to be effective at removing inϐlammatory mediators 
during CPB [10,11]. In addition, one recen.t prospective, randomized double-blind trial 
demonstrated that hemoϐiltration but not steroids results in earlier tracheal extubation 
following CPB [12]. Initially hemoϐiltration was intended to correct the accumulation 
of extravascular water during or immediately following the surgical procedure. Several 
new beneϐits have been identiϐied, such as the reduction of postoperative blood loss 
and immediate improvement in hemodynamic [13,14].
In addition, recent evidence has shown that mild renal dysfunction is a predictor of 
outcomes in terms of in-hospital mortality, morbidity, and midterm survival in patients 
undergoing coronary artery bypass graft” (CABG) surgery [15]. Since hemoϐiltration 
is well tolerated in patients with compromised circulatory status this technique has 
become useful in the postoperative period for treating patients with acute renal failure. 
Indeed, early and aggressive continuous venovenous hemoϐiltration (CVVH) has been 
associated with better than predicted survival in severe postoperative AKI [16]. 
However it is still unknown as to whether real-world outcomes of cardiac operations 
incorporating intraoperative hemoϐiltration as applied during cardiopulmonary bypass 
surgery are markedly different from those with postoperative hemoϐiltration initiated 
in intensive care units or wards. The objective of this study was to analyse real-world 
data to assess whether outcomes differ for patients with preoperative kidney disease 
treated with hemoϐiltration modalities either during CPB or 1-2 days after coronary 
artery bypass graft (CABG)” to “CABG. 
MATERIALS AND METHODS
Patients
We retrospectively followed 7620 patients who underwent on-pump ϐirst-time 
isolated cardiac bypass graft surgery between April 2001 and March 2006. All data 
were collected (Table 1) during in-patient admission as part of the routine clinical 
practice as previously described [17]. In-hospital mortality was deϐined as deaths 
within the same hospital admission regardless of cause or within 30 days of hospital 
Table 1: Unadjusted patient characteristics.
Non-HF Group
(n=7006)
Intra-Op 
HF Group (n=112)
Post-Op HF Group
(n=38) P
Age at Operation (years) 65.2 62.3 68.9 0.04
Female (%) 26.9 39.3 26.3 0.01
Body mass index (kg/m2) 27.8 27.7 27.1 0.29
Diabetes (%) 19.1 20.5 47.4 <0.01
PVD (%) 11.2 5.4 18.4 0.05
Cerebrovascular disease (%) 9.4 7.1 7.9 0.65
Respiratory disease (%) 36.5 45.5 50.0 0.03
Preoperative renal dysfunction (%) 4.2 38.4 100.0 <0.01
Hypertension (%) 57.9 50.0 67.2 0.20
Current smoker (%) 14.3 19.6 13.2 0.27
Triple-vessel disease (%) 54.9 40.2 71.1 <0.01
LMS stenosis >50% (%) 16.2 12.5 21.1 0.41
Ejection fraction <30% (%) 7.6 8.9 31.6 <0.01
Previous cardiac surgery (%) 4.2 13.4 7.9 <0.01
Non-elective surgery (%) 14.9 41.1 52.6 <0.01
Logistic EuroSCORE 6.7 16.5 26.6 <0.01
ICU length of stay (days) 2.4 7.1 13.0 <0.01
Hospital stay (days) 10.8 17.9 24.3 <0.01
LMS: left main stem; ICU: intensive care unit; PVD: peripheral vascular disease.
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discharge. Postoperative stroke was deϐined as a new focal neurological deϐicit and 
comatose states’ occurring postoperatively that persisted for 24 hours after its onset 
and was noted before discharge. Transient confused states and temporary intellectual 
impairment were not included. Postoperative myocardial infarction was deϐined 
as unequivocal ECG changes, elevation of cardiac enzyme(s) to 3 times upper limit 
of creatinine kinase (CKMB) and above twice the upper limit of normal or elevated 
troponin (T/I), and chest pain typical of ischemia lasting for more than 20 minutes. 
The European Risk Stratiϐication Score System (EuroSCORE) was used to assess risk 
associated with cardiac surgery [18].
Patients with renal dysfunction were described as those with an estimated 
glomerular ϐiltration rate (eGFR) <60 mL/minute/1.73 m2 that has persisted for at least 
3 months before the date of surgery. We stratiϐied patients into 3 groups: (1) patients 
treated with intraoperative hemoϐiltration (n=112) during cardiopulmonary bypass; 
(2) patients treated with postoperative hemoϐiltration (n=38); (3) a control group 
without hemoϐiltration use (n=7006). Patients with preoperative dialysis dependent 
renal insufϐiciency were excluded from further analysis. 
Intraoperative hemoϐiltration was applied for either secondary renal impairment 
or correction of ϐluid retention due to cardiac failure/excessive hemodilution. 
Standard intraoperative hemoϐiltration involves connecting a parallel circuit to the 
cardiopulmonary bypass via hollow ϐibre ϐilters (Polysulfone PS, Hospal Lyon, France). 
Blood ϐlow rates were maintained at 300-500 ml/min (about 10% of the pump output) 
with a transmembrane pressure of about 300 mm Hg. 
Cases of severe AKI were identiϐied postoperatively and treated with continuous 
venovenous hemoϐiltration (CVVH). AKI was as previously deϐined by the KIDGO 
consensus conference [19,20]. The technique of CVVH involved a double lumen catheter 
connected to a blood pump, through which blood was pumped into a module at ϐlow 
rates of 200 to 250 mL/m with an intravenous pump controlling the ultraϐiltration 
rate at 2 L/h. The module was also equipped with pressure alarms and an air bubble 
trap. Standard Polysulfone PS ϐilters were used in all patients. Anticoagulation of the 
circuit was performed in accordance with local clinical practice governed by duration 
of hemoϐiltration. Replacement ϐluids were administered at the pre-ϐilter stage with 
rates chosen to suit the desired ϐluid therapy goals. 
Patient follow-up
The patients were followed up through a national tracing service using patient’s 
name, National Health Service unique number and date of birth, gender, and postcode. 
Study endpoints 
The primary endpoint was the risk-adjusted freedom from death within the 5-year 
study period. Secondary outcomes include risk-adjusted in-hospital death, atrial 
ϐibrillation, myocardial infarction, stroke, re-operation for bleeding, and surgical 
wound infections. 
Statistical analyses
Due to non-normality of data, continuous variables are shown as median with 25th 
and 75th percentiles. Categorical variables are shown as a percentage. Comparisons 
were made with Kruskal-Wallis tests and Chi-square tests as appropriate. Logistic 
regression was used to risk adjust in-hospital outcomes for differences in patient and 
disease characteristics [21]. Deaths occurring as a function of time were described 
using the product limit methodology of Kaplan and Meier [22]. Cox proportional 
hazards analysis was used to calculate adjusted hazard ratios (HR) and to risk adjust 
the Kaplan-Meier survival curves [23]. Logistic EuroSCORE [18] was used for risk 
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adjustment. This approach aims to balance out patient preoperative characteristics by 
incorporating a commonly used cardiac surgery risk scoring method. In all cases a p 
value <0.05 was considered signiϐicant. All statistical analysis was performed with SAS 
for Windows Version 8.2.
RESULTS
In-hospital outcomes 
A total of 113 patients had intraoperative HF, 38 had postoperative HF and 7006 
had no HF. Tables 1 and 2, shows patient’s preoperative characteristics and in-hospital 
outcomes. In the unmatched data (Table 2), we observed increased in-hospital 
death, and re-operation for bleeding outcomes in both the HF groups as compared 
to the control group without HF. More volume was removed from the postoperative 
haemoϐiltration group (Table 2). Interestingly, all the patients in the postoperative HF 
group had preoperative renal impairment and that 97% of these patients went on to 
developed acute kidney injury that necessitated hemoϐiltration in intensive care unit. 
In contrast, 38% of the patients on intraoperative hemoϐiltration had preoperative 
renal impairment and 27% developed perioperative acute kidney injury. As shown on 
table 3, only 39.5% of patients with preoperative renal dysfunction that undergone 
intraoperative HF had AKI compared with 33.5% of those in the group that had no 
preoperative kidney impairment. This compares favourable with patients that had the 
conventional delayed postoperative CVVH where all patients who had preoperative 
kidney disease suffered AKI except one. 
The adjusted odds ratios (OR) for in hospital outcomes (Table 4) indicated that in 
both intraoperative and postoperative HF groups there was no association between 
the use of HF with in hospital strokes, re-operation for bleeding, myocardial infarction 
and surgical wound infections. In contrast, a strong association was shown with in-
hospital death for intraoperative HF (OR 2.8, CI 1.5-5.1, P<0.001) and more so in the 
postoperative HF group (OR 12.1, CI 5.7-25.6, P<0.001). Atrial ϐibrillation was also 
signiϐicantly associated with postoperative HF group but not the intraoperative HF 
group.
Table 2: Unadjusted in-hospital outcomes.
Non-HF Control Group
(n=7006)
Intra-Op 
HF Group (n=112)
Post-Op HF Group
(n=38) P
Death (%) 3.4 16.1 50.0 <0.01
Stroke (%) 2.2 1.8 2.6 0.94
Myocardial Infarction (%) 1.7 2.7 0.0 0.51
Atrial fi brillation (%) 27.8 27.7 50.0 <0.01
Re-operation for bleeding (%) 5.0 10.7 15.8 <0.01
Acute Kidney Injury (%) 6.4 23.2 97.4 <0.01
Surgical wound infection (%) 3.5 5.4 7.9 0.21
Volume removed (mL) - 2000 (800-7000) 8200 (7075-14500) 0.04
Balance (mL) - 0 (0-0) -875 (-2325-4250) 0.84
Creatinine (μmol/L) - 291 (203-739) 230 (201-273) 0.35
Table 3: Incidences of preoperative renal dysfunction and corresponding AKI rates.
No HF Intra-Op HF Post-Op HF
Preoperative renal dysfunction 296 / 7006 (4.2%) 43 / 112 (38.4%) 38 / 38 (100%)
Post-operative AKI patients 99 / 296 (33.5%) 17 / 43 (39.5%) 37 / 38 (97.4%)
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Freedom from death analysis
Freedom from death curves are shown in ϐigure 1. After adjusting for differences in 
a number of confounding factors (Figure 2), there was a signiϐicantly higher mortality 
during the follow-up period for the postoperative HF patients as compared with the 
intraoperative HF group. 
DISCUSSION
The application of hemoϐiltration before and after CABG surgery is very common for 
a number of indications including ϐluid overload and preoperative kidney impairment. 
Studies [24] have shown that up to 10% of patients sustain renal dysfunction due to 
kidney injury induced by CPB during CABG surgery [25,26]. Karkouti et al. [27], also 
demonstrated that CPB was associated with a 33.6% prevalence of postoperative 
acute kidney injury (AKI), which was associated independently with a greater than 
4-fold increase in the odds of death. The ϐindings are consistent with our observations 
of 6.4% postoperative AKI rates for patients with no history of preoperative kidney 
disease and that these rates increase signiϐicantly (3.5-15 fold) for patients with a 
history of preoperative kidney disease irrespective of the type of renal replacement 
intervention used. These ϐindings are in agreement with previous studies [15] that also 
demonstrated that preoperative mild kidney disease was highly predictive of both AKI 
and in-hospital deaths [15]. 
Mechanisms related to the occurrence of AKI in these patients is however still 
uncertain. Several studies [28-30] have previously demonstrated that renal injury 
sustained during cardiac surgery may be mechanistically related to pre-existing 
renal dysfunction, diabetes mellitus, ventricular dysfunction, older age, hypertension, 
microembolic and macroembolic processes, inϐlammatory mediators, prolonged CPB 
time, sensitivity to sympathetic stimulation, and perturbation in renovascular resistance 
and ϐlow. Indeed ϐindings from our study suggest that when data are corrected for 
pre-existing renal dysfunction, diabetes mellitus, ventricular dysfunction, older age, 
hypertension, the risk of AKI is signiϐicantly reduced for patients on intraoperative HF, 
suggesting that multiple comorbidities contribute to incidents of AKI. Interestingly, the 
incidents of AKI in patients with preoperative kidney injury were comparable to those 
Table 4: Crude and adjusted odds ratio for in-hospital outcomes.
Intra Op HF
Odds Ratio 95% CI p Value
Post Op HF
Odds Ratio 95% CI p Value
In-Hospital Mortality
Crude 5.5 3.3-9.2 <0.001 28.7 15.0-54.9 <0.001
Adjusted* 2.8 1.5-5.1 <0.001 12.1 5.7-25.6 <0.001
Stroke 
Crude 0.8 0.2 -3.3 0.77 1.2 0.2-8.9 0.85
Adjusted* 0.4 0.09 -1.6 0.19 0.4 0.05-2.9 0.34
Myocardial Infarction 
Crude 1.6 0.5-5.2 0.40 - - -
Adjusted* 1.3 0.4-4.2 0.69 - - -
Atrial Fibrillation 
Crude 1.0 0.7-1.5 0.98 2.6 1.4-4.9 0.002
Adjusted* 0.9 0.6-1.4 0.69 2.2 1.1-4.2 0.02
Re-operation for bleeding 
Crude 2.3 1.2-4.2 0.006 3.6 1.5-8.6 0.002
Adjusted* 1.8 0.9-3.3 0.08 2.0 0.8-5.1 0.13
Acute kidney injury 
Crude 4.4 2.8-6.9 <0.001 541.6 74.1->999 <0.001
Adjusted* 2.6 1.6-4.3 <0.001 340.6 46.0->999 <0.001
Surgical wound infection 
Crude 1.5 0.7-3.5 0.30 2.3 0.7-7.6 0.15
Adjusted* 1.2 0.5-2.9 0.63 1.5 0.5-5.2 0.50
* Adjusted for Logistic EuroS.
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without when intraoperative HF is given. This may suggest that intraoperative HF may 
protect patients from CPB-induced injury.
Other authors [31] have also demonstrated that the occurrence of postoperative 
mild to moderate acute kidney injury (AKI) was associated with a mortality rate of 
10% to 20%, ϐindings that are consistent with results from our study. Interestingly, AKI 
incidents in this study were associated with even much higher in-hospital mortality 
rates (50%) despite the application of postoperative CVVH. When the results are 
corrected for preoperative chronic kidney disease and other risk factors, the evidence 
also suggests that preoperative kidney disease is the single most signiϐicant risk factor 
for in-hospital mortality irrespective of renal support treatment modalities. 
Currently, there is a lack of consensus on indications for and timing of initiation 
of renal support for patients with preexisting renal impairment or those at risk of 
AKI in the perioperative period. Some studies have shown that postoperative HF 
improves outcomes if initiated early [32-36]. In contrast, others such as Bouman 
and co-workers in 2003 [37] studied the effects of the initiation time of continuous 
venovenous hemoϐiltration on patients with circulatory and respiratory insufϐiciency 
leading to oliguric AKI. The authors observed that recovery of renal function was not 
improved by using high ultraϐiltrate volumes or by early initiation of hemoϐiltration. 
In addition, other randomised studies failed to demonstrate that intensity/duration of 
renal replacement therapy could improve outcomes [38,39]. Issues remain regarding 
the proper deϐinition of AKI [19,20]. While there is an unanimous agreement that 
renal complication severely impact patient outcome, speciϐic aspects of management, 
including the method of renal replacement therapy, i.e. dialysis based on the diffusion 
principle or hemoϐiltration (based on convection); the dose of renal replacement 
therapy (Urea KT/V for dialysis vs. hemoϐiltration ϐlow (ml/kg/hour)), and the timing 
(early vs. late) of renal replacement therapy are all controversial. Even after a consensus 
Figure 1: Risk unadjusted freedom from death.
Figure 2: Risk adjusted freedom from death.
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deϐinition was put forward [the R.I.F.L.E classiϐication: 2nd Consensus Conference, 
ADQI Group [40-42], there is still great uncertainty as what is the best course of action 
when treatment decisions have to be made speciϐically aimed at patients with pre-
existing renal impairment. Existing evidence would suggest that even slightly elevated 
serum creatinine predicts AKI requiring hemoϐiltration after cardiac surgery [43]. 
Despite the limitations, our study is the ϐirst to show that in high risk category of 
patients with pre-existing renal impairment, hemoϐiltration during cardiopulmonary 
bypass can minimise incidences of postoperative AKI or has survival beneϐits. 
Based on the observation from our study that patients with high preoperative 
risk scores (EuroSCORE >16.1) are at increased risk of further renal impairment we 
hypothesize that it is these types of patients who could derive signiϐicant beneϐits from 
intraoperative hemoϐiltration. Indeed our most recent randomised controlled trial on 
intraoperative hemoϐiltration during cardiac surgery for patients with preoperative 
chronic kidney disease demonstrated superior outcomes as compared with treatment 
as usual. This is in terms of signiϐicant reduction in rates of pulmonary infections 
and in-hospital deaths compared with a control usual care group without the use of 
intraoperative hemoϐiltration [44].
The randomised trial [44] appear to support the ϐindings from this real-world study 
setting that after adjusting for case mixes intraoperative hemoϐiltration is associated 
with more favourable short term outcomes such as in-hospital death and reduced risk 
of atrial ϐibrillation as compared with equivalent patients that received the traditional 
delayed postoperative hemoϐiltration care. 
The underlying mechanisms for these beneϐits have yet to be elucidated. It is 
possible that the beneϐits of intraoperative hemoϐiltration (conventional or modiϐied 
ultraϐiltration) can be explained by the elimination of inϐlammatory mediators during 
the metabolic stressful period of coronary bypass, as demonstrated in studies before 
[6-10]. In addition, there is also evidence to suggest that intraoperative hemoϐiltration 
reduces levels of S100b release and cognitive dysfunction [11], resulting in an earlier 
tracheal extubation following cardiopulmonary bypass [12]. In other studies it has 
also been shown that intraoperative hemoϐiltration may reduce the requirement for 
post-operative blood transfusion, also increase BP and cardiac index immediately after 
hemoϐiltration [45]. 
In conclusion, ϐindings from this study support the hypothesis that the use of 
intraoperative hemoϐiltration may offer short term clinical beneϐits and improve 
longer-term survival for patients with preoperative kidney disease. In contrast, the 
delayed use of postoperative hemoϐiltration on patients with known preoperative 
kidney impairment does not signiϐicantly impact occurrence of AKI and the impact of 
AKI on survival. It is with this reasoning and evidence from other studies [46-48] that 
we hypothesize that for patients with preoperative kidney disease routine application 
of intraoperative haemoϐiltration or early CVVH rather than the traditional delayed 
CVVH (which is commonly started 1-3 days after CABG in response to mostly oliguria 
symptoms and electrolytes imbalance) may improve outcomes of these vulnerable 
patients. The recent introduction of hemodialϐiltration techniques incorporating 
citrate-based regional anticoagulation systems soon after CPB may be a game changer 
for patients with preoperative kidney disease in routine clinical practice [49]. 
STUDY LIMITATIONS
Although our study included a large sample of patients undergoing coronary artery 
bypass surgery, it was not a prospective randomised trial, and therefore had a number 
of limitations. For example, patients who received HF on bypass were likely to have 
had less severe renal impairment and a lower EuroSCORE, and therefore this might 
impact upon the results giving the Intra-Op HF Group a better outcome because they 
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were going to do well regardless. Our study, however, considered three unselected 
study groups of patients on the basis of use and timing of hemoϐiltration and therefore 
provides an insight into real practice. In addition, the follow-up data obtained via 
the National Institute of Statistics only provided us with knowledge of the survival 
status without the cause of death or differentiation between cardiovascular or other 
cause of death. We also do not have data on the underlying pathophysiology of renal 
dysfunction in the patients included in the study. The ϐindings however suggest that 
a well-designed randomised study would offer a better evaluation of the treatment 
strategies for this group of patients.
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